Form D · Pharmaceuticals
Lusaris Therapeutics, Inc.
Morrisville, NC · CIK 0001953017
Offering snapshot reported Dec 6, 2022 · SEC filing
- Reported sold
- $60.2M Offering amount: $60.2M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 13, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 6, 2022 | Initial | $60,156,164 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-466642
Source: Form D, filed Dec 6, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Neil Buckley | Executive |
| Ramin Farzaneh Far | Executive |
| Daniel Grau | Director |
| Andrew Levin | Director, Executive |
| Edward Monaghan | Director, Executive, Promoter |
| Catherine Riesen | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
630 Davis Drive, Suite 220
Morrisville, NC, 27560
Morrisville, NC, 27560